難治てんかんに対するロフラゼプ酸エチルの効果  [in Japanese] The Effect of Ethyl Loflazepate on Refractory Epilepsy  [in Japanese]

Access this Article

Search this Article

Author(s)

Abstract

小児期発症の難治てんかん患者41例にロフラゼプ酸エチル (LOF) を追加使用して、その効果を検討した。1) 使用開始1ヵ月の時点の有効率は60.9%であったが、3ヵ月以上継続後には34.1%に低下した。2) てんかん類型では症候性全般てんかん、発作型では強直発作に有効な傾向がみとめられた。3) 脳波上、広汎性てんかん発射に対して有効な傾向をみとめた。4) 各症例における最大使用量とその時の血中濃度にはR=0.691で有意な相関をみとめた。5) 副作用は20例 (48.8%) にみとめられたが、軽度であった。

In order to evaluate the effect of ethyl loflazepate (LOF), we performed a clinical and electroencephalographic study on patients with childhood refractory epilepsy.<BR>We investigated the effect of LOF add-on therapy on clinical seizures and EEGs as well as side effects in 41 patients, ranging in age from 3 months to 23 years 6 months. The patients were treated with LOF for at least three months.<BR>LOF had marked or moderate effects in 25 patients (60.9%). However, in 11 patients, these effects were transient and disappeared within the first three months. LOF was more effective for symptomatic generalized epilepsy than other types of epilepsy. LOF was most effective for brief tonic seizures or tonic seizures. Epileptic discharges were suppressed or decreased in five of 14 patients who responded well to LOF. The maximum dose was well correlated with blood level (R=0.691). Twenty patients (49%) showed mild side effects, such as sleepiness and hypersalivation.

Journal

  • Journal of the Japan Epilepsy Society

    Journal of the Japan Epilepsy Society 18(2), 133-139, 2000-06-30

    JAPAN EPILEPSY SOCIETY

References:  9

Cited by:  1

Codes

  • NII Article ID (NAID)
    10008556282
  • NII NACSIS-CAT ID (NCID)
    AN10043823
  • Text Lang
    JPN
  • Article Type
    Journal Article
  • ISSN
    09120890
  • Data Source
    CJP  CJPref  J-STAGE 
Page Top